UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 171

Sortiert nach

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

The Journal of infectious diseases, 2014-08, Vol.210 (3), p.354-362

2014

Volltextzugriff (PDF)

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

JAMA : the journal of the American Medical Association, 2000-01, Vol.283 (3), p.381

2000

Volltextzugriff (PDF)

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel

JAMA : the journal of the American Medical Association, 2004-07, Vol.292 (2), p.251

2004

Volltextzugriff (PDF)

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel

JAMA : the journal of the American Medical Association, 2002-07, Vol.288 (2), p.222

2002

Volltextzugriff (PDF)

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

JAMA : the journal of the American Medical Association, 1998-07, Vol.280 (1), p.78

1998

Volltextzugriff (PDF)

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel

Clinical infectious diseases, 2008-07, Vol.47 (2), p.266-285

2008

Volltextzugriff (PDF)

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

The Lancet (British edition), 2013-03, Vol.381 (9868), p.735-743

2013

Volltextzugriff (PDF)

An open-label assessment of TMC 125: a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

AIDS (London), 2003-12, Vol.17 (18), p.F49-F54

2003

Volltextzugriff (PDF)

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

JAMA : the journal of the American Medical Association, 1997-06, Vol.277 (24), p.1962

1997

Volltextzugriff (PDF)

Underpowered clinical trials of antiretroviral treatment

JAMA : the journal of the American Medical Association, 2002-11, Vol.288 (17), p.2120; author reply 2120

2002

Volltextzugriff (PDF)

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA

JAMA : the journal of the American Medical Association, 1996-07, Vol.276 (2), p.146

1996

Volltextzugriff (PDF)

Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy–Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals

Clinical infectious diseases, 2018-05, Vol.66 (11), p.1762-1769

2018

Volltextzugriff (PDF)

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

The Lancet infectious diseases, 2013-07, Vol.13 (7), p.587-596

2013

Volltextzugriff (PDF)

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

The Lancet (British edition), 2014-06, Vol.383 (9936), p.2222-2231

2014

Volltextzugriff (PDF)

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

The New England journal of medicine, 2008-07, Vol.359 (4), p.339-354

2008

Volltextzugriff (PDF)

Silicic volcanism on Mars evidenced by tridymite in high-SiO₂ sedimentary rock at Gale crater

Proceedings of the National Academy of Sciences - PNAS, 2016-06, Vol.113 (26), p.7071-7076

2016

Volltextzugriff (PDF)

Sorafenib Alleviates Inflammatory Signaling of Tumor Microenvironment in Precancerous Lung Injuries

Pharmaceuticals (Basel, Switzerland), 2023-02, Vol.16 (2), p.221

2023

Volltextzugriff (PDF)

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

The New England journal of medicine, 2008-07, Vol.359 (4), p.355-365

2008

Volltextzugriff (PDF)

The effect of microcomputed tomography scanning and reconstruction voxel size on the accuracy of stereological measurements in human cancellous bone

Bone (New York, N.Y.), 2004-12, Vol.35 (6), p.1375-1382

2004

Volltextzugriff (PDF)

Deficient LEF1 expression is associated with lithium resistance and hyperexcitability in neurons derived from bipolar disorder patients

Molecular psychiatry, 2021-06, Vol.26 (6), p.2440-2456

2021

Volltextzugriff (PDF)

Age-related differences in identification and discrimination of temporal cues in speech segments

The Journal of the Acoustical Society of America, 2006-04, Vol.119 (4), p.2455-2466

2006

Volltextzugriff (PDF)

High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial

Clinical infectious diseases, 2009-11, Vol.49 (9), p.1441-1449

2009

Volltextzugriff (PDF)

Gag Mutations Can Impact Virological Response to Dual-Boosted Protease Inhibitor Combinations in Antiretroviral-Naïve HIV-Infected Patients

Antimicrobial Agents and Chemotherapy, 2010-07, Vol.54 (7), p.2910-2919

2010

Volltextzugriff (PDF)

1 – 25 von 171

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(163)
Mit Volltextzugriff
(141)

Publikationsform

Artikel
(169)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(135)
Science & Technology
(133)
Life Sciences & Biomedicine
(124)
Male
(102)
Infectious Diseases
(98)
Female
(95)
Adult
(91)
Biological And Medical Sciences
(83)
Medical Sciences
(78)
Hiv Infections - Drug Therapy
(77)
Middle Aged
(72)
Human Immunodeficiency Virus
(71)
Hiv
(63)
Human Viral Diseases
(58)
Viral Diseases
(58)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(52)
Microbiology
(50)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(44)
Pharmacology. Drug Treatments
(44)
Viral Load
(44)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

An open-label assessment of TMC 125: a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

Underpowered clinical trials of antiretroviral treatment

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA

Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy–Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Silicic volcanism on Mars evidenced by tridymite in high-SiO₂ sedimentary rock at Gale crater

Sorafenib Alleviates Inflammatory Signaling of Tumor Microenvironment in Precancerous Lung Injuries

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial

The effect of microcomputed tomography scanning and reconstruction voxel size on the accuracy of stereological measurements in human cancellous bone

Deficient LEF1 expression is associated with lithium resistance and hyperexcitability in neurons derived from bipolar disorder patients

Age-related differences in identification and discrimination of temporal cues in speech segments

High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial

Gag Mutations Can Impact Virological Response to Dual-Boosted Protease Inhibitor Combinations in Antiretroviral-Naïve HIV-Infected Patients

Suchergebnisse filtern